Page 40 - Demo

%u0421%u043e%u0441%u0438%u043d %u0414.%u041d., %u0425%u0430%u0441%u0430%u043d%u043e%u0432%u0430 %u0410.%u041a. %u0438 %u0434%u0440.40 %u2116 4/2024 %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430 %u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430 %u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 www.psypharma.ru36. Devonshire H., Kong I., Cooper M. et al. The contribution of genetically determined oxidation status to inter- individual variation in phenacetin disposition // Br J Clin Pharmacol. %u2013 1983. %u2013 Vol. 16 (2). %u2013 P%u0440. 157%u2013166. %u2013 https://doi.org/10.1111/j.1365-2125.1983.tb04980.x36. Devonshire H., Kong I., Cooper M. et al. The contribution of genetically determined oxidation status to inter- individual variation in phenacetin disposition // Br J Clin Pharmacol. %u2013 1983. %u2013 Vol. 16 (2). %u2013 P%u0440. 157%u2013166. %u2013 https://doi.org/10.1111/j.1365-2125.1983.tb04980.x37. Barrangou-Poueys-Darlas M., Guerlais M., Laforgue E.-J. et al. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation // Drug Metab Rev. %u2013 2021. %u2013 Vol. 53 (1). %u2013 P%u0440. 30%u201344. %u2013 https://doi.org/10.1080/03602532.2020.185952837. Barrangou-Poueys-Darlas M., Guerlais M., Laforgue E.-J. et al. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation // Drug Metab Rev. %u2013 2021. %u2013 Vol. 53 (1). %u2013 P%u0440. 30%u201344. %u2013 https://doi.org/10.1080/03602532.2020.185952838. Olsson E., Edman G., Bertilsson L. et al. Genetic and clinical factors affecting plasma clozapine concentration // Prim Care Companion CNS Disord. %u2013 2015. %u2013 https://doi.org/10.4088/pcc.14m0170438. Olsson E., Edman G., Bertilsson L. et al. Genetic and clinical factors affecting plasma clozapine concentration // Prim Care Companion CNS Disord. %u2013 2015. %u2013 https://doi.org/10.4088/pcc.14m0170439. Browning S.L., Tarekegn A., Bekele E. et al. CYP1A2 is more variable than previously thought: A genomic biography of the gene behind the human drug-metabolizing enzyme // Pharmacogenet Genomics. %u2013 2010. %u2013 Vol. 20 (11). %u2013 P%u0440. 647%u2013664. %u2013 https://doi.org/10.1097/fpc.0b013e32833e90eb39. Browning S.L., Tarekegn A., Bekele E. et al. CYP1A2 is more variable than previously thought: A genomic biography of the gene behind the human drug-metabolizing enzyme // Pharmacogenet Genomics. %u2013 2010. %u2013 Vol. 20 (11). %u2013 P%u0440. 647%u2013664. %u2013 https://doi.org/10.1097/fpc.0b013e32833e90eb40. Waring R.H. Cytochrome P450: Genotype to phenotype // Xenobiotica. %u2013 2020. %u2013 Vol. 50 (1). %u2013 P%u0440. 9%u201318. %u2013 https://doi.org/10.1080/00498254.2019.164891140. Waring R.H. Cytochrome P450: Genotype to phenotype // Xenobiotica. %u2013 2020. %u2013 Vol. 50 (1). %u2013 P%u0440. 9%u201318. %u2013 https://doi.org/10.1080/00498254.2019.164891141. Blaisdell J., Mohrenweiser H., Jackson J. et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19 // Pharmacogenetics. %u2013 2002. %u2013 Vol. 12 (9). %u2013 P%u0440. 703%u2013711. %u2013 https://doi.org/10.1097/00008571-200212000-0000441. Blaisdell J., Mohrenweiser H., Jackson J. et al. Identification and functional characterization of new potentially defective alleles of human CYP2C19 // Pharmacogenetics. %u2013 2002. %u2013 Vol. 12 (9). %u2013 P%u0440. 703%u2013711. %u2013 https://doi.org/10.1097/00008571-200212000-0000442. Botton M.R., Whirl-Carrillo M., Del Tredici A. L. et al. PharmVar GeneFocus: CYP2C19 // Clin Pharmacol Ther. %u2013 2021. %u2013 Vol. 109 (2). %u2013 P%u0440. 352%u2013366. %u2013 https://doi.org/10.1002/cpt.197342. Botton M.R., Whirl-Carrillo M., Del Tredici A. L. et al. PharmVar GeneFocus: CYP2C19 // Clin Pharmacol Ther. %u2013 2021. %u2013 Vol. 109 (2). %u2013 P%u0440. 352%u2013366. %u2013 https://doi.org/10.1002/cpt.197343. Rao S. Uppugunduri C., Daali Y., Desmeules J. et al. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity // Curr Drug Metab. %u2013 2012. %u2013 Vol. 13 (8). %u2013P%u0440. 1196%u20131204. %u2013 https://doi.org/10.2174/13892001280285014643. Rao S. Uppugunduri C., Daali Y., Desmeules J. et al. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity // Curr Drug Metab. %u2013 2012. %u2013 Vol. 13 (8). %u2013P%u0440. 1196%u20131204. %u2013 https://doi.org/10.2174/13892001280285014644. Taylor C., Crosby I., Yip V. et al. A Review of the important role of CYP2D6 in pharmacogenomics // Genes (Basel). %u2013 2020. %u2013 Vol. 11 (11). %u2013 Art. 1295. %u2013 ttps://doi.org/10.3390/genes1111129544. Taylor C., Crosby I., Yip V. et al. A Review of the important role of CYP2D6 in pharmacogenomics // Genes (Basel). %u2013 2020. %u2013 Vol. 11 (11). %u2013 Art. 1295. %u2013 ttps://doi.org/10.3390/genes1111129545. Pan X., Ning M., Jeong H. Transcriptional regulation of CYP2D6 expression // Drug Metabolism and Disposition. %u2013 2017. %u2013 Vol. 45 (1). %u2013 P%u0440. 42%u201348. %u2013 https://doi.org/10.1124/dmd.116.07224945. Pan X., Ning M., Jeong H. Transcriptional regulation of CYP2D6 expression // Drug Metabolism and Disposition. %u2013 2017. %u2013 Vol. 45 (1). %u2013 P%u0440. 42%u201348. %u2013 https://doi.org/10.1124/dmd.116.07224946. Seo J., Lee C.R., Paeng J.C. et al. Biallelic mutations in ABCB1 display recurrent reversible encephalopathy // Ann Clin Transl Neurol. %u2013 2020. %u2013 Vol. 7 (8). %u2013 P%u0440. 1443%u20131449. %u2013 https://doi.org/10.1002/acn3.5112546. Seo J., Lee C.R., Paeng J.C. et al. Biallelic mutations in ABCB1 display recurrent reversible encephalopathy // Ann Clin Transl Neurol. %u2013 2020. %u2013 Vol. 7 (8). %u2013 P%u0440. 1443%u20131449. %u2013 https://doi.org/10.1002/acn3.5112547. Moons T., de Roo M., Claes S., Dom G. Relationship between P-glycoprotein and secondgeneration antipsychotics // Pharmacogenomics. %u2013 2011. %u2013 Vol. 12 (8). %u2013 P%u0440. 1193%u20131211. %u2013 https://doi.org/10.2217/pgs.11.5547. Moons T., de Roo M., Claes S., Dom G. Relationship between P-glycoprotein and secondgeneration antipsychotics // Pharmacogenomics. %u2013 2011. %u2013 Vol. 12 (8). %u2013 P%u0440. 1193%u20131211. %u2013 https://doi.org/10.2217/pgs.11.5548. Lee S.-T., Ryu S., Kim S.R. et al. Association study of 27 annotated genes for clozapine pharmacogenetics // J Clin Psychopharmacol. %u2013 2012. %u2013 Vol. 32 (4). %u2013 P%u0440. 441%u2013448. %u2013 https://doi.org/10.1097/jcp.0b013e31825ac35c48. Lee S.-T., Ryu S., Kim S.R. et al. Association study of 27 annotated genes for clozapine pharmacogenetics // J Clin Psychopharmacol. %u2013 2012. %u2013 Vol. 32 (4). %u2013 P%u0440. 441%u2013448. %u2013 https://doi.org/10.1097/jcp.0b013e31825ac35c49. Breitenstein B., Br%u00fcckl T.M., Ising M. et al. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis // American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. %u2013 2015. %u2013 Vol. 168 (4). %u2013 P%u0440. 274%u2013283. %u2013https://doi.org/10.1002/ajmg.b.3230949. Breitenstein B., Br%u00fcckl T.M., Ising M. et al. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis // American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. %u2013 2015. %u2013 Vol. 168 (4). %u2013 P%u0440. 274%u2013283. %u2013https://doi.org/10.1002/ajmg.b.3230950. Br%u00fcckl T.M., Uhr M. ABCB1 genotyping in the treatment of depression // Pharmacogenomics. %u2013 2016. %u2013 Vol. 17 (18). %u2013 P%u0440. 2039%u20132069. %u2013 https://doi.org/10.2217/pgs.16.1850. Br%u00fcckl T.M., Uhr M. ABCB1 genotyping in the treatment of depression // Pharmacogenomics. %u2013 2016. %u2013 Vol. 17 (18). %u2013 P%u0440. 2039%u20132069. %u2013 https://doi.org/10.2217/pgs.16.1851. Li M., Mei L., He C. et al. Extrusion pump ABCC1 was first linked with nonsyndromic hearing loss in humans by stepwise genetic analysis // Genet Med. %u2013 2019. %u2013 Vol. 21 (12). %u2013P%u0440. 2744%u20132754. %u2013 https://doi.org/10.1038/s41436-019-0594-y51. Li M., Mei L., He C. et al. Extrusion pump ABCC1 was first linked with nonsyndromic hearing loss in humans by stepwise genetic analysis // Genet Med. %u2013 2019. %u2013 Vol. 21 (12). %u2013P%u0440. 2744%u20132754. %u2013 https://doi.org/10.1038/s41436-019-0594-y52. Tukey R.H., Strassburg C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract // Mol Pharmacol. %u2013 2001. %u2013 Vol. 59 (3). %u2013 P%u0440. 405%u2013414. %u2013 https://doi.org/10.1124/mol.59.3.40552. Tukey R.H., Strassburg C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract // Mol Pharmacol. %u2013 2001. %u2013 Vol. 59 (3). %u2013 P%u0440. 405%u2013414. %u2013 https://doi.org/10.1124/mol.59.3.40553. Malhi V., Nowicka M., Chen Y.C. et al. UGT1A4 Polymorphism is not associated with a clinically relevant change in giredestrant exposure // Cancer Chemother Pharmacol. %u2013 2024. %u2013 Vol. 94 (1). %u2013 P%u0440. 117%u2013122.53. Malhi V., Nowicka M., Chen Y.C. et al. UGT1A4 Polymorphism is not associated with a clinically relevant change in giredestrant exposure // Cancer Chemother Pharmacol. %u2013 2024. %u2013 Vol. 94 (1). %u2013 P%u0440. 117%u2013122.54. Breyer-Pfaff U., Wachsmuth H. Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine // Drug Metab Dispos. %u2013 2001. %u2013 Vol. 29 (10). %u2013P%u0440. 1343%u20131348.54. Breyer-Pfaff U., Wachsmuth H. Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine // Drug Metab Dispos. %u2013 2001. %u2013 Vol. 29 (10). %u2013P%u0440. 1343%u20131348.55. Mori A., Maruo Y., Iwai M. et al. UDP-glucuronosyltransferase 1a4 polymorphisms in a japanese population and kinetics of clozapine glucuronidation // Drug Metabolism and Disposition. %u2013 2005. %u2013 Vol. 33 (5). %u2013 P%u0440. 672%u2013675. %u2013 https://doi.org/10.1124/dmd.104.00257655. Mori A., Maruo Y., Iwai M. et al. UDP-glucuronosyltransferase 1a4 polymorphisms in a japanese population and kinetics of clozapine glucuronidation // Drug Metabolism and Disposition. %u2013 2005. %u2013 Vol. 33 (5). %u2013 P%u0440. 672%u2013675. %u2013 https://doi.org/10.1124/dmd.104.00257656. Marcuello E., Alt%u0435%ue088s A., Menoyo A. et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer // Br J Cancer. %u2013 2004. %u2013 Vol. 91 (4). %u2013P%u0440. 678%u2013682. %u2013ttps://doi.org/10.1038/sj.bjc.660204256. Marcuello E., Alt%u0435%ue088s A., Menoyo A. et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer // Br J Cancer. %u2013 2004. %u2013 Vol. 91 (4). %u2013P%u0440. 678%u2013682. %u2013ttps://doi.org/10.1038/sj.bjc.660204257. Erickson-Ridout K.K., Sun D., Lazarus P. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms // Pharmacogenet Genomics. %u2013 2012. %u2013 Vol. 22 (8). %u2013 P%u0440. 561%u2013576. %u2013 ttps://doi.org/10.1097/fpc.0b013e328354026b57. Erickson-Ridout K.K., Sun D., Lazarus P. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms // Pharmacogenet Genomics. %u2013 2012. %u2013 Vol. 22 (8). %u2013 P%u0440. 561%u2013576. %u2013 ttps://doi.org/10.1097/fpc.0b013e328354026b58. Yuen J.W.Y., Kim D.D., Procyshyn R.M. et al. A focused review of the metabolic side-effects of clozapine // Front Endocrinol (Lausanne). %u2013 2021. %u2013 Vol. 12. %u2013 Art. 609240. %u2013https://doi.org/10.3389/fendo.2021.60924058. Yuen J.W.Y., Kim D.D., Procyshyn R.M. et al. A focused review of the metabolic side-effects of clozapine // Front Endocrinol (Lausanne). %u2013 2021. %u2013 Vol. 12. %u2013 Art. 609240. %u2013https://doi.org/10.3389/fendo.2021.609240